X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter Financial Results

X4 Pharmaceuticals (XFOR) Reports In-Line Q2 EPS

August 3, 2021 8:09 AM EDT

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of ($0.74), in-line with the analyst estimate of ($0.74).

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

... More